Market Overview

Jefferies Reiterates Buy on Amarin Corporation on Continued Positive Outlook

Related AMRN
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
FDA Approvals And Changes For The Week Ending February 14, 2014

In a report published Thursday, Jefferies analyst Thomas Wei reiterated a Buy rating and $20.00 price target on Amarin Corporation plc (NASDAQ: AMRN).

In the report, Jefferies noted, “We outline several reasons why we remain positive on near term approval prospects for the Vascepa ANCHOR indication in advance of the advisory committee meeting set for October 16 and the expected release of the FDA's briefing documents on Friday (October 11). The ANCHOR Indication of mixed dyslipidemia is critical for long-term Vascepa sales growth and we view it as central to our AMRN Buy thesis.”

Amarin Corporation plc closed on Wednesday at $6.30.

Posted-In: Jefferies Thomas WeiAnalyst Color Reiteration Analyst Ratings

 

Most Popular

Related Articles (AMRN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free